Ferrari (NYSE:RACE) Bolsa

Ferrari

Ferrari designs, engineers, and manufactures some of the world's most expensive luxury cars. With supply carefully controlled to be below demand and a brand steeped in decades of motor racing history, a Ferrari is viewed as a status symbol. In 2024, the company sold 13,752 vehicles at an average price over EUR 480,000 with more than 70% of its vehicles being sold to existing Ferrari clients. Eighty-six percent of revenue is generated from the sale of cars and spare parts and 10% from sponsorship, commercial, and brand activities including racing and lifestyle activities. In 2024, the Europe, Middle East, and Africa region accounted for 47% of revenue, the Americas was 33%, mainland China, Hong Kong, and Taiwan was 8%, and the rest of Asia was 12%.

Cars,For,Sale

Long Ideas

Tech

Trading Ideas

NSANY

RACE

STLA

TSLA

VWAGY

Los fabricantes de automóviles sufren caídas tras los nuevos aranceles de Trump. Cómo afectan al mercado y si hay oportunidades de inversión.

Acciones de automóviles caen tras nuevos aranceles de Trump: ¿Oportunidad de compra?

AAPL

BMWYY

MERCEDES-BENZ UNSP / ADR by Mercedes Benz Group AG

MBGYY

Porsche Automobile Holding SE Unsponsored

POAHY

Descubre por qué las acciones de las principales compañías automotrices están cayendo y cómo el coche eléctrico está alterando el mercado.

El motor europeo se toma una pausa en bolsa

Ferrari NV

Race Oncology Ltd

Benchmark analyst Cody Acree maintains Marvell Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVL#NASDAQ">MRVL</a>) with a Buy and lowers the price target from $135 to $95.

News

Price Target

Analyst Ratings

MRVL

Benchmark Maintains Buy on Marvell Tech, Lowers Price Target to $95

The ODP Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ODP#NASDAQ">ODP</a>) shares are trading higher on Wednesday after the first-quarter FY25 earnings. The company reported <a href="https://www.benzinga.com/pressreleases/25/05/b45247761/the-odp-corporation-announces-first-quarter-2025-results">first-quarter revenue decline </a>of 9.1% year-on-year to $1.70 billion, beating the analyst consensus estimate of $1.67 billion.
The decrease in reported sales is largely related to lower sales in its Office Depot Division, primarily due to 46 fewer retail locations in service compared to the previous year and reduced retail and online consumer traffic, as well as lower sales in its ODP Business Solutions Division.
Also Read: <a href="https://www.benzinga.com/25/05/45236630/ford-outperforms-in-q1-faces-tariff-challenges-ahead-say-analysts">Nike Revamps C-Suite, &#8216;Win Now&#8217; Strategy Faces Profit Pressure: Analyst</a>
Gross profit decreased 11.8% to $360 million with a margin of 21.2%. Selling, general and administrative expenses dropped 10.3% to $306 million.
The company reported an operating loss of $32 million compared to an operating income of $41 million, a 178% decrease.
Adjusted EBITDA for the quarter decreased 16.5% to $76 million. Adjusted EPS of $1.06 <a href="https://www.benzinga.com/earnings">beat the analyst consensus</a> estimate of $0.65. It fell 19% year-on-year from $1.31.
Operating cash flow for the quarter totaled $57 million with a free cash flow of $36 million. 
The company held $185 million in cash and equivalents as of March 29. Total debt was $262 million.
"We are off to a better start to the year, with our overall performance reflecting positive momentum and improving trends in the first quarter," said CEO Gerry Smith.
&#8220;We&#8217;re also closely monitoring the tariff environment, and while we are not immune to shifts in policy, we have taken actions to help mitigate potential impacts.&#8221;
Price Action: ODP shares traded higher by 1.17% to $13.79 at the last check on Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/05/45262160/why-terra-chips-maker-hain-celestials-stock-is-plummeting-today">Terra Chips Maker Hain Celestial Seeks Strategic Options For Business, Announces CEO Transition, Stock Tanks</a></li>
</ul>
Image by Hrach Hovhannisyan via Shutterstock

Earnings

Movers

General

Office Depot CEO Says It Can Mitigate Potential Tariffs Impact After Q1 Profit Dip

<a href="https://www.bloomberg.com/news/articles/2025-05-07/robinhood-said-to-plan-blockchain-to-trade-us-assets-in-europe">https://www.bloomberg.com/news/articles/2025-05-07/robinhood-said-to-plan-blockchain-to-trade-us-assets-in-europe</a>

HOOD

'Robinhood Plans Blockchain to Trade US Assets in Europe'- Bloomberg

<a href="https://www.youtube.com/watch?v=M1STr27Vbts" title="https://www.youtube.com/watch?v=M1STr27Vbts">https://www.youtube.com/watch?v=M1STr27Vbts</a>

Macro Economic Events

Economics

Federal Reserve

Fed Chair Powell Says Avoiding Persistent Inflation Will Depend On Size, Timing Of Tariffs, And Inflation Expectations; We Aim To Inflation Expectations Anchored; Without Price Stability Cannot Achieve Strong Labor Conditions; If Dual Mandate Goals In Tension, Consider Distance From Goal, Time To Close Gaps; Time To Wait Before Adjusting Policy; Tariffs' Longer Term Impact On Inflation Not Clear Yet

Conduent Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNDT#NASDAQ">CNDT</a>) shares are trading lower on Wednesday after the <a href="https://www.benzinga.com/pressreleases/25/05/g45249980/conduent-reports-first-quarter-2025-financial-results" target="_blank" rel="noreferrer noopener">company reported first-quarter results.</a>
Conduent registered adjusted earnings per share of 13 cents loss, beating the Street view of a 15 cents loss. Quarterly sales of $751 million (down 18.5% year over year) missed the analyst consensus estimate of $778.33 million.
The company reported adjusted EBITDA of $37 million, up 2.8% year-over-year. Adjusted EBITDA Margin expanded by 50 bps year over year to 4.9%.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/05/45259295/whats-going-on-with-icahn-enterprises-stock-today" rel="noreferrer noopener">What&#8217;s Going On With Icahn Enterprises Stock Today?</a>
&#8220;Our portfolio rationalization efforts are being reinvigorated with additional opportunities and are on track toward achieving more than $1B in deployable capital,&#8221; said Cliff Skelton, Conduent president and CEO. 
New business signings ACV stood at $109 million, while net ARR activity over the trailing 12 months reached $116 million.
At the end of the quarter, Conduent&#8217;s liquidity position included $293 million of cash and a $550 million revolving credit facility largely undrawn.
&#8220;Fortunately, while macro-economic and geopolitical environments affect everyone, most of our business segments are somewhat insulated from trade and government efficiency challenges, and in some cases, may benefit from opportunities,&#8221; the CEO added.
Outlook: Conduent reaffirmed its FY2025 sales guidance of $3.10 billion to $3.25 billion, compared to the $3.19 billion consensus estimate.
CNDT Price Action: Conduent shares are trading lower by 2.44% to $2 at publication on Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/05/45252150/novo-nordisk-expects-fda-decision-for-oral-wegovy-by-end-of-2025-reports-mixed-q1-earnings" target="_blank" rel="noreferrer noopener">Novo Nordisk's Wegovy Sales Surge 85% But Compounded Weight Loss Drugs In US Impacts Annual Outlook</a></li>
</ul>

Equities

Guidance

Markets

CNDT

What's Going On With Conduent Stock On Wednesday?

Fed Chair Powell Says Consumers, Businesses Report Lower Sentiment In Surveys;  Labor Market Not A Source Of Significant Inflation Pressure; Near-Term Inflation Expectations Have Moved Up; Survey Respondents Point To Tariffs As Driving Inflation Expectations; Longer-Term Inflation Expectations Consistent With Goal; Tariffs So Far Significantly Bigger Than Expected;  If Large Increases In Tariffs As Announced Are Sustained, Will See Higher Inflation, Lower Employment

For years, people made the same joke: "Does &#8216;Edible Arrangements&#8217; sell edibles?"
Now, it does.
Edible Brands—the parent company behind the fruit bouquet giant with more than 800 locations and roughly $500 million in annual revenue—has officially entered the cannabis-adjacent space. But instead of leaning into novelty, the company is positioning itself as a responsible operator in a murky and fast-growing category: hemp-derived THC.
Its new venture, Edibles.com, launched earlier this year as a curated e-commerce marketplace offering low-dose THC products from brands like Cann, Wana, 1906 and Happi. While the site's branding is light on references to Edible Arrangements, the infrastructure and ambition behind it reflect the scale of a company that has delivered fruit bouquets to millions.
"We've had this idea for a long time," said CEO Somia Farid Silber in an exclusive interview with <a href="https://www.benzinga.com/cannabis">Benzinga Cannabis</a>. "It was kind of this casual, running joke—‘Do you sell edibles?'—but once we owned the domain, we realized we had an opportunity to build something trusted. Something that helps people live better, not just get high."
<h2 class="wp-block-heading">&#8216;You Want To Come Into This Space? Why?&#8216;</h2>
When Thomas Winstanley, former chief marketing officer at craft cannabis company Theory Wellness, first heard about the project, he didn't quite get it.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="873" height="1024" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/07121104/Thomas_Headshot-Plaid-873x1024.jpg" alt="" class="wp-image-906114" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/07121104/Thomas_Headshot-Plaid-873x1024.jpg 873w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/07121104/Thomas_Headshot-Plaid-256x300.jpg 256w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/07121104/Thomas_Headshot-Plaid-768x901.jpg 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/07121104/Thomas_Headshot-Plaid-1310x1536.jpg 1310w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/07121104/Thomas_Headshot-Plaid-1747x2048.jpg 1747w" sizes="(max-width: 873px) 100vw, 873px" /></figure>
Photo: Thomas Winstanley
"I was skeptical at first," he admitted. "It was like—wait, you have edibles.com? You want to come into this space? Why?"
Winstanley, who'd helped build one of the East Coast's most recognized cannabis brands, had seen how messy the industry could be. He didn't want to be the "weed guy they brought in" just to slap THC labels on fruit baskets.
Also read: <a href="https://www.benzinga.com/markets/cannabis/25/05/42033985/the-broccoli-hack-how-mexican-creators-bypassed-tiktoks-rules-to-teach-millions-about-cannabis">The Broccoli Hack: How Mexican Creators Bypassed TikTok&#8217;s Rules To Teach Millions About Cannabis</a>
But as he dug deeper, he saw something rare: infrastructure. Edible Brands had a high-performing e-commerce system that processed roughly $300 million in annual sales, a nationwide last-mile delivery network and leadership that was genuinely interested in doing it right.
"I didn't want to come in like a bull in a china shop and just try to peddle a bunch of products," he said. "What drew me in was the opportunity to build something with integrity, something rooted in wellness."
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="824" height="1024" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/07121035/elg_somia59-824x1024.jpg" alt="" class="wp-image-906113" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/07121035/elg_somia59-824x1024.jpg 824w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/07121035/elg_somia59-241x300.jpg 241w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/07121035/elg_somia59-768x955.jpg 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/07121035/elg_somia59-1235x1536.jpg 1235w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/07121035/elg_somia59-1647x2048.jpg 1647w" sizes="(max-width: 824px) 100vw, 824px" /></figure>
Photo: Somia Farid Silber
Farid Silber had already positioned Edibles.com as a standalone platform—separate from Edible Arrangements, but powered by the same operational backbone.
"We're building out a platform that's all about gifting, food, health and wellness," she said. "This is the wellness part."
<h2 class="wp-block-heading">Not Your Typical Dispensary</h2>
Edibles.com doesn't sell THC-laced strawberries or cannabis-infused gift towers. And that's the point.
Instead of mimicking Edible Arrangements' gifting model, the site launched as a curated online marketplace with clean design, a limited product selection and no gimmicks. It features gummies, drinks and lozenges from trusted third-party hemp brands. No house products—for now. No novelty packaging.
"We might do something like that in the future," said Farid Silber, referring to the idea of THC-infused gifts. "But today, it's really about creating a space where we can highlight all these amazing brands—and using our last-mile delivery advantage to get products to consumers quickly and affordably."
The absence of gifting isn't philosophical; it's logistical. While hemp-derived THC is federally legal under the 2018 Farm Bill, state rules vary widely. In Georgia, for example, consumers can find high-dose Delta-9 products at gas stations. But shipping a curated THC gift box across multiple states? That's much trickier.
"For now, we're focused on personal use and building trust," Farid Silber said.
Winstanley put it more bluntly: "I don't want to send my mom a gift box of THC chews that she thinks are candy, especially when she has no idea what's in them, how strong they are or how much to take."
<h2 class="wp-block-heading">A New Kind Of Wellness</h2>
While the name might suggest a party crowd, Edibles.com leans heavily into functionality and wellness, positioning THC as an alternative to alcohol or a tool for better sleep and stress management.
"When you're introducing a product category with this much baggage and confusion, you have to meet consumers where they are," Winstanley said. "This is about offering a safer, more straightforward way for people to try or access THC."
Farid Silber, who's new to the cannabis industry, said her own learning curve helped shape the platform's focus on education.
Also read: <a href="https://www.benzinga.com/markets/cannabis/25/04/44992856/willy-wonka-of-weed-opens-the-doors-to-the-raw-factory-heres-what-we-saw">&#8216;Willy Wonka Of Weed&#8217; Opens The Doors To The RAW Factory: Here&#8217;s What We Saw</a>
"There's just so much out there," she said. "What's the difference between CBD and CBN? What's right for sleep? For energy? We want Edibles.com to be a destination where people can learn and shop safely without feeling overwhelmed or judged."
Over time, the company hopes to build a broader content hub covering cannabis, nutraceuticals and wellness tools. For now, the focus is simple: low-dose THC, clear information and a judgment-free experience.
<h2 class="wp-block-heading">Gas Station Gummies And Executive Confusion</h2>
For consumers in states without dispensaries, the THC experience often starts in less-than-ideal places.
"I was totally blown away," Winstanley said. "Seeing a thousand-milligram chew in a gas station was scary. Coming from regulated cannabis, it felt really foreign—and really dangerous."
Even internally, the lack of awareness was jarring.
"One executive told me, ‘Oh, I just went to a dispensary and got these products,'" Winstanley recalled. "And I had to say—no, you didn't. There are no dispensaries here."
That, he said, underscores the brand's larger mission: to help people distinguish between vetted products and random street-level stuff.
"We want to be a trusted marketplace," he said. "For that, you have to curate."
<h2 class="wp-block-heading">Scaling Up—With Caution</h2>
The company's first phase launched in Texas, followed by Georgia, the Carolinas and Florida. All were chosen for a reason: they represent large populations underserved by cannabis infrastructure.
"Last mile in Texas was phase one," Winstanley said. "Now that we know the engine runs, it's time to scale."
Nationwide shipping is next. And in Atlanta, Edibles.com is opening its first flagship retail store, designed to mirror the e-commerce experience but offer in-person support.
Also read: <a href="https://www.benzinga.com/markets/cannabis/25/04/39798605/dreka-gates-cannabis-would-be-a-trillion-dollar-industry-for-black-and-brown-communities-if-it-h">Dreka Gates: &#8216;Cannabis Would Be A Trillion-Dollar Industry For Black And Brown Communities—If It Hadn&#8217;t Been Criminalized&#8217;</a>
"It gives people a place to talk to someone and walk out with something in hand," he said. "In a state without dispensaries, that's a big deal."
A franchise model is on the table, potentially offering a "dispensary-lite" opportunity for operators who want to sell low-dose THC without the cost or red tape of traditional licensing.
<h2 class="wp-block-heading">Regulation, Risk And Why Hemp Might Get It Right</h2>
Winstanley tracks hemp regulations "almost daily," especially in states like Texas and Florida. But he doesn't view oversight as a threat. In fact, he welcomes it.
"I would never have said this back when I was in cannabis," he told Benzinga, "but regulation in this category can be a net positive. It helps weed out bad actors. It legitimizes good ones. And it creates a safer space for the consumer."
He cited Texas's SB3 bill, which originally aimed to ban hemp-derived THC, as a turning point. The bill stalled after an 18-hour hearing where residents spoke passionately in defense of the category.
"There's growing awareness that policy needs to catch up to reality," he said. "Legalization happened. Now we need to frame it responsibly."
That includes pushing for milligram caps, licensing models and clear enforcement that preserves access while protecting consumers.
<h2 class="wp-block-heading">In-House Products? Eventually</h2>
With its infrastructure and reach, it's only a matter of time before Edibles.com launches its own branded line.
"We know what we want to make," Winstanley said. "But we're not rushing. This isn't about putting our name on something and flooding the site. It's about finding the right partners, the right formulations and the right voice."
He previously managed more than 250 SKUs at Theory Wellness and helped launch one of the first automated cannabis canning lines on the East Coast. Still, this time, the team is taking it slow.
"We could go out and slap a label on a bag of chews tomorrow," he said. "But that's not the kind of company we are. We want to do it right—and that means learning first, then launching."
<h2 class="wp-block-heading">This Isn't A Joke; It's A Business</h2>
Edibles.com may have launched with a wink and a clever domain name, but the team behind it isn't playing for laughs.
"This is something serious," Farid Silber said. "We know the name gets attention, but we didn't build this to go viral or be cute. We built it to help people live better. And that only works if you build it right."
So far, the gamble seems to be paying off. The company hasn't shared early sales figures, but reports an "overwhelmingly positive" response. With expansion underway, a flagship store in development and a potential franchise model on the horizon, Edibles.com is positioning itself for real staying power.
It may not look like cannabis retail as we know it, but that's kind of the point.
Photos courtesy of Edible Brands

Cannabis

Exclusives

Interview

They Turned Fruit Bouquets Into A $500 Million-A-Year Business—Now They're Selling THC. Here's Why

Fed Chair Powell Says Inflation Has Come Down A Great Deal; Running Somewhat Above 2% Goal; Current Stance Of Policy Leaves Us Well Positioned To Respond In Timely Way; Import Swing Complicated GDP Data; The Risks Of Higher Unemployment, Higher Inflation Have Risen; Remains To Be Seen How Uncertainty Affects Future Spending And Investment;  Labor Market Broadly In Balance; Labor Market Consistent With Max Employment

COSM

Cosmos Health Receives Addl Purchase Order For 80,000 Units From Pharmalink For Sky Premium Life Products In United Arab Emirates

<a href="https://www.washingtonpost.com/business/2025/05/07/elon-musk-starlink-trump-tariffs/" title="https://www.washingtonpost.com/business/2025/05/07/elon-musk-starlink-trump-tariffs/">https://www.washingtonpost.com/business/2025/05/07/elon-musk-starlink-trump-tariffs/</a>

Global

'U.S. Pushes Nations Facing Tariffs To Approve Musk's Starlink, Cables Show' - Washington Post

CRISPR Therapeutics AG (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRSP#NASDAQ">CRSP</a>) reported new topline study results on Wednesday to establish risk factors for <a href="https://www.benzinga.com/general/biotech" target="_blank" rel="noreferrer noopener">atherosclerotic heart disease</a>.
The company disclosed data regarding the first 10 patients across its Phase 1 first-in-human dose escalation trial, targeting ANGPTL3 in four patient groups with elevated low-density lipoprotein (LDL), triglyceride (TG), or both.
The data comes from the first 10 patients across the first four cohorts (lean body weight-based doses of DL1 [0.1 mg/kg], DL2[0.3 mg/kg], DL3 [0.6 mg/kg] and DL4 [0.8 mg/kg]) with at least 30 days of follow-up for each participant as of a data <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/g45234774/crispr-therapeutics-provides-first-quarter-2025-financial-results-and-announces-positive-top-line-" rel="noreferrer noopener">cutoff date of April 16</a>.
A single dose of CTX310 demonstrated dose-dependent decreases in ANGPTL3, TGs, and LDL.
<ul>
<li>Based on ANGPTL3 knockdown, DL1 and DL2 were minimally active doses, whereas treatment at DL3 and DL4 reduced up to 75% of baseline levels in ANGPTL3.</li>
<li>A DL4 patient with sHTG had an 82% reduction in triglycerides from a baseline of 1073 mg/dL at day 30, and a DL3 patient with HeFH had an 81% reduction in LDL-C from a baseline of 256 mg/dL at day 90 – supporting the potential for targeted efficacy in high-risk populations.</li>
</ul>
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/05/45254051/vinay-prasads-appointment-to-fdas-cber-triggers-questions-over-future-of-cell-and-gene-therapy-regulation" rel="noreferrer noopener">Vinay Prasad&#8217;s Appointment To FDA&#8217;s CBER Triggers Questions Over Future Of Cell And Gene Therapy Regulation</a>
CTX310 has been well-tolerated, with no treatment-related severe adverse events (SAEs) and no grade ≥3 adverse events (AEs) reported.
<ul>
<li>No clinically significant changes in alanine aminotransferase (ALT), aspartate aminotransferase (AST), bilirubin, or platelets were observed at any dose level. There were no dose-dependent trends in any of these laboratory measurements.</li>
</ul>
The company plans to present the CTX310 Phase 1 data at a medical meeting in the second half of 2025.
Chardan Research lowered the <a href="https://www.benzinga.com/quote/CRSP/analyst-ratings" target="_blank" rel="noreferrer noopener">price target from $84 to $82</a> on Wednesday, with a Buy rating.
Chardan analyst Geulah Livshits writes, &#8220;Topline PI results for CTX310 indicate safety and activity, though more detailed data in 2H25 will help understand competitiveness.&#8221;
On Wednesday, CRISPR reported that cash, cash equivalents, and marketable securities were $1.85 billion as of March 31.
The topline readout did not include patient-level data. They also comprise of results from patients with a range of disease pathologies, which could contribute to variability. However, the biomarker numbers generally align with &#8220;benchmarks set by RNAi assets for ANGPTL3,&#8221; Livshits adds.
The CRISPR&#8217;s update, plus Verve Therapeutics Inc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERV#NASDAQ">VERV</a>) <a href="https://www.benzinga.com/25/04/44793762/verve-therapeutics-touts-positive-data-from-gene-editing-medicine-to-lower-cholesterol-after-single-dose" target="_blank" rel="noreferrer noopener">data on its second-generation</a> PCSK9 gene editor, points to a promising balance of benefits and risks for gene-editing treatments.
The analyst also combed through CBER Director Vinay Prasad&#8216;s social media. Commentary reveals criticism of Verve&#8217;s 1st-gen PCSK9 approach/data. This may signal negative sentiment for advanced therapies that CRSP, Verve and other players might need to navigate, Livshits says.
Health Secretary Robert F. Kennedy picked Prasad to be the Food and Drug Administration&#8217;s vaccine regulator. Prasad replaces former CBER Director Peter Marks, who Kennedy forced to resign. 
Price Action: CRSP stock is up 2.99% at $34.15 at the last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/05/45257579/johnson-controls-surpasses-q2-revenue-and-earnings-estimates-raises-eps-guidance-for-2025" target="_blank" rel="noreferrer noopener">Johnson Controls Surpasses Q2 Revenue And Earnings Estimates, Raises EPS Guidance For 2025</a></li>
</ul>

Analyst Color

Biotech

Health Care

CRSP

VERV

CRISPR Therapeutics' Data Shows Promise, But RFK Jr. Appointee Could Be Negative: Analyst

WIIM

SPDR Dow Jones Industrial Average ETF Trust

Major indexes are lower after the Fed left rates unchanged and said economic uncertainty has increased.

The Federal Reserve kept its fed funds rate steady at 4.25%-4.50% on Wednesday, a widely expected move that marks the third consecutive <a href="https://www.benzinga.com/topic/federal-reserve">pause in interest-rate policy. </a>
"Uncertainty about the economic outlook has increased further," the Fed noted in its post-meeting statement. 
The May meeting was the first since President Donald Trump's early April announcement of new trade tariffs.
The Federal Reserve noted that recent indicators point to continued solid growth in economic activity, while hinting that volatility in net exports has distorted the data, a reference to the negative GDP reading in the first quarter.
Yet, the Committee emphasized that "risks of higher unemployment and higher inflation have risen," introducing this new language into the May policy statement.
The Fed reiterated its data-dependent stance, emphasizing that future policy actions will be assessed "meeting by meeting," based on economic data, the evolving outlook, and balance of risks. This measured approach suggests that policymakers remain flexible in their response to shifting economic conditions.
Attention now turns to Fed Chair Jerome Powell, who is scheduled to hold his presser at 2:30 p.m. ET. Powell is expected to field questions on the implications of the Trump tariffs, recession risks, inflation trajectory, and the growing political pressure from Trump, who has publicly called for lower interest rates.
Read also: <a href="https://www.benzinga.com/economics/macro-economic-events/25/05/45258146/all-eyes-on-powell-what-betting-markets-expect-him-to-say-wednesday">All Eyes On Powell: What Betting Markets Expect Him To Say Wednesday</a>
Leading into the decision, futures markets were pricing in a 28% probability of a 25-basis-point rate cut by the June meeting, rising to 73% by July. Traders currently anticipate approximately 65 basis points of easing by the end of 2025, equivalent to nearly three standard rate cuts.
Minutes prior to the Fed statement, speaking at the swearing-in ceremony for the new U.S. ambassador to China, President Trump said he has no intention of rolling back the 145% tariffs on Chinese goods and is not seeking a broad range of tariff exemptions.
<h3 class="wp-block-heading">Market reactions </h3>
Stocks remained broadly unchanged minutes after the Federal Open Market Committee statement. 
The S&amp;P 500 index – as tracked by the SPDR S&amp;P 500 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) – was trading at 5,608 points, flat on the day. 
The U.S. dollar index – followed by the  Invesco DB USD Index Bullish Fund ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UUP#NYSE">UUP</a>) – fell slightly.
Treasury yields trended lower, with yields on the 10-year Treasury note falling from 4.29% to 4.26%. 
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/25/05/45224205/will-powell-defy-trump-again-heres-what-the-fed-chair-might-say-on-wednesday">Will Powell Defy Trump Again? Here&#8217;s What The Fed Chair Might Say On Wednesday</a></li>
</ul>
Photo: RozenskiP / Shutterstock.com

Broad U.S. Equity ETFs

Econ #s

ETFs

PowerShares DB US Dollar Index Bullish Fund

Fed Keeps Rates Steady, Warns Of Rising 'Uncertainty About The Economic Outlook'

S&P Reverses, Turns Negative After Fed Leaves Key Overnight Rate Unchanged

Cencora, Inc&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COR#NYSE">COR</a>) on Wednesday reported second-quarter 2025 sales increased 10.3% to $75.5 billion, missing the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $75.68 billion</a>, primarily due to an 11.4% increase in revenue within the U.S. Healthcare Solutions segment.
U.S. Healthcare Solutions revenue was $68.3 billion, due to overall market growth primarily driven by unit volume growth, including increased sales of products labeled for diabetes and/or weight loss in the GLP-1 class and specialty products to physician practices and health systems.
The company reported adjusted EPS of $4.42, up 16.3% year over year, beating the&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/b45247410/cencora-reports-fiscal-2025-second-quarter-results" rel="noreferrer noopener">consensus of $4.11</a>.
Adjusted gross profit in the second quarter of fiscal 2025 was $2.9 billion, a 15.2% year-over-year increase, due to the increase in gross profit in the U.S. Healthcare Solutions segment, offset in part by the decrease in gross profit in the International Healthcare Solutions segment. 
Also Read:&nbsp;<a target="_blank" href="https://www.benzinga.com/25/02/43557922/debt-strategy-in-motion-walgreens-early-cencora-share-settlement-unlocks-300-million" rel="noreferrer noopener">Walgreens Cashes In: Slashes Cencora Stake Again In Debt-Fighting Move</a>
Adjusted gross profit margin was 3.86%, an increase of 16 basis points. Adjusted operating income was $1.2 billion, a 15.3% increase, driven by an increase in the U.S. Healthcare Solutions segment, partially offset by a decrease in the International Healthcare Solutions segment. Margin was 1.58% in the fiscal 2025 second quarter, an increase of seven basis points when compared to the prior year quarter.
Guidance:&nbsp;Cencora updated its fiscal year 2025 financial guidance to reflect stronger earnings growth in the U.S. Healthcare Solutions segment and a lower contribution from the International Healthcare Solutions segment.
Cencora expects adjusted diluted EPS of $15.70-$15.95, up from prior guidance of $15.30-$15.60, compared to the consensus of $15.46.
International Healthcare Solutions segment revenue growth to be in the range of 3%-4%, down from the previous range of 4%-5%.
Adjusted consolidated operating income growth to be between 13.5%-15.5%, up from the previous range of 11.5%-13.5%.
COR Price Action: Cencora stock is up 4.71% at $304.505 at publication on Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/05/45259295/whats-going-on-with-icahn-enterprises-stock-today" target="_blank" rel="noreferrer noopener">What&#8217;s Going On With Icahn Enterprises Stock Today?</a></li>
</ul>
Photo: Shutterstock

Cencora's Boosts Annual Forecast On Strong Demand For Weight Loss Drugs, Specialty Products Despite Mixed Q2 Earnings

Mizuho analyst Ben Chaiken maintains Marriott International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAR#NASDAQ">MAR</a>) with a Neutral and lowers the price target from $293 to $285.

Mizuho Maintains Neutral on Marriott International, Lowers Price Target to $285

Stewart Information Servs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STC#NYSE">STC</a>) is gearing up to announce its quarterly earnings on Wednesday, 2025-04-23. Here's a quick overview of what investors should know before the release.
Analysts are estimating that Stewart Information Servs will report an earnings per share (EPS) of $0.34.
Anticipation surrounds Stewart Information Servs's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
<h3>Earnings Track Record</h3>
During the last quarter, the company reported an EPS beat by $0.15, leading to a 3.91% increase in the share price on the subsequent day.

<img src="https://www.benzinga.com/files/images/story/2025/1746641166_0.png" alt="eps graph" />
<h3>Performance of Stewart Information Servs Shares</h3>
Shares of Stewart Information Servs were trading at $64.98 as of May 06. Over the last 52-week period, shares are up 1.57%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<a href="https://www.benzinga.com/quote/STC/earnings">To track all earnings releases for Stewart Information Servs visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insights Ahead: Stewart Information Servs's Quarterly Earnings

Mizuho analyst Vijay Rakesh maintains Rivian Automotive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>) with a Neutral and raises the price target from $10 to $11.

RIVN

Mizuho Maintains Neutral on Rivian Automotive, Raises Price Target to $11

S&P Moves Higher After Fed Leaves Key Overnight Rate Unchanged

Investors with a lot of money to spend have taken a bearish stance on Amgen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with AMGN, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://www.benzinga.com/pro/">Benzinga</a>'s options scanner spotted 19 uncommon options trades for Amgen.
This isn't normal.
The overall sentiment of these big-money traders is split between 26% bullish and 68%, bearish.
Out of all of the special options we uncovered, 13 are puts, for a total amount of $1,826,748, and 6 are calls, for a total amount of $452,930.
<h3>Predicted Price Range</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $250.0 to $315.0 for Amgen over the last 3 months. 
<h3>Volume &amp; Open Interest Trends</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Amgen's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Amgen's whale trades within a strike price range from $250.0 to $315.0 in the last 30 days. 
<h3>Amgen Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1746641003_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>AMGN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$21.65</td>
<td>$21.15</td>
<td>$21.65</td>
<td>$290.00</td>
<td>$433.0K</td>
<td>1.9K</td>
<td align="right">404</td>
</tr>
<tr>
<td>AMGN</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$9.45</td>
<td>$9.0</td>
<td>$9.37</td>
<td>$260.00</td>
<td>$421.6K</td>
<td>755</td>
<td align="right">451</td>
</tr>
<tr>
<td>AMGN</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$20.8</td>
<td>$20.2</td>
<td>$20.8</td>
<td>$290.00</td>
<td>$257.9K</td>
<td>1.9K</td>
<td align="right">204</td>
</tr>
<tr>
<td>AMGN</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$20.6</td>
<td>$20.3</td>
<td>$20.6</td>
<td>$290.00</td>
<td>$195.7K</td>
<td>1.9K</td>
<td align="right">499</td>
</tr>
<tr>
<td>AMGN</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$20.25</td>
<td>$19.3</td>
<td>$20.25</td>
<td>$290.00</td>
<td>$155.9K</td>
<td>1.9K</td>
<td align="right">77</td>
</tr>
</tbody>
</table>

<h3>About Amgen</h3>
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
Having examined the options trading patterns of Amgen, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Current Position of Amgen</h3>
<ul>
<li>With a trading volume of 917,451, the price of AMGN is up by 1.85%, reaching $275.45.</li>
<li>Current RSI values indicate that the stock is is currently neutral between overbought and oversold.</li>
<li>Next earnings report is scheduled for 90 days from now.</li>
</ul>
<h3>What Analysts Are Saying About Amgen</h3>
5 market experts have recently issued ratings for this stock, with a consensus target price of $312.8.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from RBC Capital keeps a Outperform rating on Amgen with a target price of $320. 
&#x2A; Maintaining their stance, an analyst from UBS continues to hold a Neutral rating for Amgen, targeting a price of $315. 
&#x2A; An analyst from Mizuho has decided to maintain their Neutral rating on Amgen, which currently sits at a price target of $280. 
&#x2A; Consistent in their evaluation, an analyst from UBS keeps a Neutral rating on Amgen with a target price of $319. 
&#x2A; Maintaining their stance, an analyst from Morgan Stanley continues to hold a Equal-Weight rating for Amgen, targeting a price of $330. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Amgen, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.

Options

AMGN

What the Options Market Tells Us About Amgen

Press Releases

DIVIDEND DISTRIBUTION PROPOSAL

FERRARI RELEASES ITS 2024 ANNUAL REPORT AND FILES ANNUAL REPORT ON FORM 20-F

Ferrari: Announcement of the Seventh Tranche of the Multi-Year Share Repurchase Program by Participating as a Purchaser in Exor's Accelerated Bookbuild Offering

Comments

Ferrari

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL